Biopharmaceutical

Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic

Friday, March 27, 2020 - 10:19pm

We at Abeona are thankful for their sacrifices and efforts, and stand behind these healthcare institutions whose resources are focused on the greater good.

Key Points: 
  • We at Abeona are thankful for their sacrifices and efforts, and stand behind these healthcare institutions whose resources are focused on the greater good.
  • Abeona is fully focused on getting through the pandemic by working closely with our clinical trial sites to ensure that patient safety remains paramount.
  • Abeona is about great Science and great People, and its important we continue to do everything we can to preserve both.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases.

Aquavit Pharmaceuticals, Inc. Announces Filing of New Patent Applications for a New Drug Delivery Platform and Vaccine Compositions for Immunizing Patients Against COVID-19 Caused by the SARS-CoV-2 Coronavirus

Friday, March 27, 2020 - 2:37pm

The patent applications cover platform technologies directed to novel methods for immunizing patients against infectious diseases such as COVID-19 using microchannel delivery devices.

Key Points: 
  • The patent applications cover platform technologies directed to novel methods for immunizing patients against infectious diseases such as COVID-19 using microchannel delivery devices.
  • Aquavit's microchannel technology overcomes the existing problems of vaccine delivery while also avoiding bleeding and pain that are normally associated with commercially available immunization methods.
  • Aquavit Pharmaceuticals, Inc., located in New York City, is developing several innovative products and platform technology IP for personalized medicine.
  • The company's mission is to modernize and personalize healthcare for patients through innovative drug and biologics delivery systems.

Shareholder Alert: Robbins LLP Reminds Investors Allakos, Inc. (ALLK) Sued for Misleading Shareholders

Thursday, March 26, 2020 - 11:51pm

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Allakos, Inc. (NASDAQ: ALLK) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 5, 2019 and December 17, 2019.

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Allakos, Inc. (NASDAQ: ALLK) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 5, 2019 and December 17, 2019.
  • Allakos is a clinical stage biopharmaceutical company that focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases.
  • If you suffered a loss as a result of Allakos' misconduct, click here .
  • According to the complaint, on August 5, 2019, Allakos announced that its drug AK002 had met all pre-specified primary and secondary endpoints in its Phase 2 clinical trial (the "ENIGMA Trial").

Arvelle Announces European Medicines Agency Acceptance of the Marketing Authorization Application for Cenobamate

Thursday, March 26, 2020 - 1:23pm

Zug, Switzerland, 26 March 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announces that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for cenobamate for the adjunctive treatment of focal-onset seizures in adults with epilepsy.

Key Points: 
  • Zug, Switzerland, 26 March 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announces that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for cenobamate for the adjunctive treatment of focal-onset seizures in adults with epilepsy.
  • Commenting on the news, Mark Altmeyer, President and CEO of Arvelle Therapeutics, said: The acceptance of the MAA marks an important milestone for Arvelle.
  • Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market.
  • In early 2019, SK Biopharmaceuticals entered into an exclusive licensing agreement with Arvelle Therapeutics to develop and commercialize cenobamate in Europe.

RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN

Thursday, March 26, 2020 - 1:15pm

We are excited about this regulatory filing for osilodrostat in Japan which, if approved, will provide a new and convenient oral treatment option that will help address patients needs in this underservedpatient population said Andrea Recordati, CEO.

Key Points: 
  • We are excited about this regulatory filing for osilodrostat in Japan which, if approved, will provide a new and convenient oral treatment option that will help address patients needs in this underservedpatient population said Andrea Recordati, CEO.
  • is a biopharmaceutical company committed to providing often-overlooked orphan therapies to the underserved rare disease communities in Japan.
  • Recordati Rare Diseases' mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies.
  • Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases.

 ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing

Thursday, March 26, 2020 - 12:00pm

ReCode Therapeutics (ReCode) (the Company), a private biopharmaceutical company pioneering precision medicines for pulmonary diseases, today announced the close of an oversubscribed $80 million Series A financing round.

Key Points: 
  • ReCode Therapeutics (ReCode) (the Company), a private biopharmaceutical company pioneering precision medicines for pulmonary diseases, today announced the close of an oversubscribed $80 million Series A financing round.
  • Our preclinical studies demonstrate that our targeted RNA therapies have great potential for the treatment of life-threatening pulmonary diseases, commented David Lockhart, Ph.D., CEO and president, ReCode Therapeutics.
  • We are pleased to close this financing round with world-class investors who believe in the bold vision of our new company.
  • Chardan acted as sole placement agent on the Series A financing, and as M&A advisor to ReCode Therapeutics.

Apexigen To Present At The Upcoming 2020 Solebury Trout Virtual Investor Conference

Thursday, March 26, 2020 - 11:00am

SAN CARLOS, Calif., March 26, 2020 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, plans to present an overview of the company at the upcoming Solebury Trout Virtual Investor Conference.The 25-minute presentation includes an interactive Q&A with participants prompted to submit questions electronically.

Key Points: 
  • SAN CARLOS, Calif., March 26, 2020 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, plans to present an overview of the company at the upcoming Solebury Trout Virtual Investor Conference.The 25-minute presentation includes an interactive Q&A with participants prompted to submit questions electronically.
  • APX005M and Apexigen's other programs were discovered using Apexigen's proprietary APXiMAB discovery platform.
  • This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies.
  • Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees.

Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates

Thursday, March 26, 2020 - 11:30am

CAMBRIDGE, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided corporate updates.

Key Points: 
  • CAMBRIDGE, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided corporate updates.
  • LPC has agreed not to cause or engage in any direct or indirect short selling or hedging of Unum Therapeutics common stock.
  • Unum Therapeutics maintains the right to terminate the common stock purchase agreement at any time, at its discretion, without any additional cost or penalty.
  • Unum Therapeutics is a biopharmaceutical company focused on developing curative cell therapies to treat patients with solid tumor cancers.

Karuna Therapeutics to Participate in Stifel’s 2nd Annual CNS Day Virtual Event

Thursday, March 26, 2020 - 11:00am

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics will participate in a panel presentation at Stifels 2nd Annual CNS Day Virtual Event on Wednesday, April 1, 2020.

Key Points: 
  • Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics will participate in a panel presentation at Stifels 2nd Annual CNS Day Virtual Event on Wednesday, April 1, 2020.
  • Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders which remain among the most disabling and potentially fatal disorders worldwide.
  • For more information, please visit karunatx.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005100/en/

CStone Pharmaceuticals Reports 2019 Annual Financial Results

Thursday, March 26, 2020 - 10:25am

SHANGHAI, March 26, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and molecularly-targeted precision medicines for the treatment of cancer, today released its audited annual financial results for the year ended December 31, 2019.

Key Points: 
  • SHANGHAI, March 26, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and molecularly-targeted precision medicines for the treatment of cancer, today released its audited annual financial results for the year ended December 31, 2019.
  • "2019 was a transformational year for the company as we continued to advance the development of our IO and precision medicine products.
  • "In 2019, we presented key data of our three IO backbone assets, which have demonstrated promising safety and efficacy profiles.
  • The Company will host a live conference call and webcast at 10AM HKT, March 27, 2020 to present its financial results for the year ended December 31, 2019.